Lymphatic system: A vital link between metabolic syndrome and inflammation

Annals of the New York Academy of Sciences

Volumn 1207, Issue SUPPL.1, 2010, Pages

  Chakraborty, Sanjukta ^a   Zawieja, Scott ^a   Wang, Wei ^a   Zawieja, David C ^a   Muthuchamy, Mariappan ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Inflammation; Lymphatic pump; Lymphatics and lipid transport; Metabolic syndrome

Indexed keywords

CHEMOKINE; CYTOKINE; INSULIN; LIPID;

HUMAN; HYPERLIPIDEMIA; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; LIPID TRANSPORT; LYMPH FLOW; LYMPH NODE; LYMPHATIC SYSTEM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; ADIPOSE TISSUE; ANIMAL; LIPID METABOLISM; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RAT;

ADIPOSE TISSUE; ANIMALS; HUMANS; INFLAMMATION; LIPID METABOLISM; LYMPHATIC SYSTEM; METABOLIC SYNDROME X; MICE; RATS;

EID: 85047687451     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05752.x     Document Type: Review

References (89)

1. Grundy, S.M. 2004. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89: 2595-2600.
2. Grundy, S.M., J.L. Cleeman, S.R. Daniels, et al. 2005. Diagnosis and management of themetabolic syndrome: anAmericanHeart Association/NationalHeart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
3. Basciano, H., L. Federico and K. Adeli. 2005. Fructose, insulin resistance, and metabolic dyslipidemia.Nutr.Metab. (Lond.) 2: 5.
4. Feskens, E.J., S.M. Virtanen, L. R̈as̈anen, et al. 1995. Dietary factors determining diabetes andimpaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 18: 1104-1112.
5. Hill, J.O., D. Lin, F. Yakubu, et al. 1992. Development of dietary obesity in rats: influence of amount and composition of dietary fat. Int. J.Obes. Relat. Metab. Disord. 16: 321-333.
6. Romieu, I., W.C. Willett, M.J. Stampfer, et al. 1988. Energy intake and other determinants of relativeweight. Am. J. Clin. Nutr. 47: 406-412.
7. Liu, S. and J.E. Manson. 2001. Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease. Curr. Opin. Lipidol. 12: 395-404.
8. Pearson, T.A., G.A. Mensah, R.W. Alexander, et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511.
9. Trayhurn, P. and I.S. Wood. 2004. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92: 347-355.
10. You, T., R. Yang, M.F. Lyles, et al. 2005. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors.Am. J. Physiol. Endocrinol.Metab. 288: E741-E747.
11. Ross, R., J. Freeman, R. Hudson, et al. 2002. Abdominal obesity, muscle composition and insulin resistance in premenopausal women. J. Clin. Endocrinol. Metab. 87: 5044-5051.
12. Mittelman, S.D., G.W. Van Citters, E.L. Kirkman, et al. 2002. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 51: 755-761.
13. Mauri'ege, P., A. Marette, C. Atgié, et al. 1995. Regional variation in adipose tissue metabolism of severely obese premenopausal women. J. Lipid Res. 36: 672-684.
14. Després, J.P. and I. Lemieux. 2006. Abdominal obesity and metabolic syndrome. Nature 444: 881-887.
15. Miteva, D.O., J.M. Rutkowski, J.B. Dixon, et al. 2010. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ. Res. 106: 920-931.
16. Iqbal, J. and M.M. Hussain. 2009. Intestinal lipid absorption. Am. J. Physiol. Endocrinol.Metab. 296: E1183-E1194
17. Harvey, N.L. 2008. The link between lymphatic function and adipose biology. Ann. N.Y. Acad. Sci. 1131: 82-88.
18. Dixon, J.B. 2010. Lymphatic lipid transport: sewer or subway? Trends Endocrinol. Metab. 21: 480-487.
19. Muthuchamy, M. and D. Zawieja. 2008. Molecular regulation of lymphatic contractility. Ann. N.Y. Acad. Sci. 1131: 89-99.
20. Zawieja, D. 2005. Lymphatic biology and the microcirculation: past, present and future. Microcirculation 12: 141-150.
21. Gashev, A.A. and D.C. Zawieja. 2010. Hydrodynamic regulation of lymphatic transport and the impact of aging. Pathophysiology 17: 277-287.
22. Von der Weid, P.Y. and M. Muthuchamy. 2010. Regulatory mechanisms in lymphatic vessel contraction under normal and inflammatory conditions. Pathophysiology 17: 263-276.
23. Mislin, H. 1961. Experimental detection of autochthonous automatism of lymph vessels. Experientia 17: 29-30.
24. Mislin, H. 1966. Structural and functional relations of the mesenteric lymph vessels. New Trends in Basic Lymphology, Proceedings of a Symposium held at Charleroi (Belgium), July 11-13, 1966. Experientia Suppl. 14: 87-96.
25. Allen, J.M. and N.G. Mchale. 1986. Neuromuscular transmission in bovine mesenteric lymphatics. Microvasc. Res. 31: 77-83.
26. Zawieja, D.C., K.L. Davis, R. Schuster, et al. 1993. Distribution, propagation, and coordination of contractile activity in lymphatics. Am. J. Physiol. 264: H1283-H1291.
27. Mchale, N.G. and M.K. Meharg. 1992. Co-ordination of pumping in isolated bovine lymphatic vessels. J. Physiol. 450: 503-512.
28. Crowe, M.J., P.Y. von der Weid, J.A. Brock and D.F. Van Helden. 1997.Coordination of contractile activity in guineapig mesenteric lymphatics. J. Physiol. 500: 235-244.
29. Leak, L. and J. Burke. 1968. Ultrastructural studies on the lymphatic anchoring filaments. J. Cell Biol. 36: 129-149.
30. Collin, H. 1969. The ultrastructure of conjunctival lymphatic anchoring filaments. Exp. Eye Res. 8: 102-105.
31. Leak, L.V. 1976. The structure of lymphatic capillaries in lymph formation. Fed. Proc. 35: 1863-1871.
32. Muthuchamy, M., A. Gashev, N. Boswell, et al. 2003.Molecular and functional analyses of the contractile apparatus in lymphatic muscle. FASEB J. 17: 920-922.
33. Gashev, A.A., M.J. Davis and D.C. Zawieja. 2002. Inhibition of the active lymph pump by flow in rat mesenteric lymphatics and thoracic duct. J. Physiol. 540: 1023-1037.
34. Gashev, A.A., M.J. Davis, M.D. Delp, et al. 2004. Regional variations of contractile activity in isolated rat lymphatics. Microcirculation 11: 477-492.
35. Warren, A.G., H. Brorson, L.J. Borud, et al. 2007. Lymphedema: a comprehensive review. Ann. Plast. Surg. 59: 464-472.
36. Phan, C.T and P. Tso. 2001. Intestinal lipid absorption and transport. Front. Biosci. 6: D299-D319.
37. Ee, L.C., S. Zheng, L. Yao, et al. 2000. Lymphatic absorption of fatty acids and cholesterol in the neonatal rat. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G325-G331.
38. Collan, Y. and T.V. Kalima. 1970. The lymphatic pump of the intestinal villus of the rat. Scand. J. Gastroenterol. 5: 187-196.
39. Fanous, M.Y., A.J. Phillips and J.A.Windsor. 2007.Mesenteric lymph: the bridge to future management of critical illness. JOP 8: 374-99.
40. Nanjee, M.N., et al. 2001.Composition and ultra structure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids. J. Lipid Res. 42: 639-648.
41. Hayashi, H., K. Fujimoto, J.A. Cardelli, et al. 1990. Fat feeding increases size, but not number of chylomicrons produced by small intestine. J. Physiol. 259: G709-G719.
42. Miura, S., E. Sekizuka, H. Nagata, et al. 1987. Increased lymphocyte transport by lipid absorption in rat mesenteric lymphatics. Am. J. Physiol. 253: G596-G600.
43. NordskogB.K., C.T.Phan, D.F.Nutting, et al. 2001.Anexamination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv. Drug Deliv. Rev. 50: 21-44.
44. Tso, P. and J.A. Balint. 1986. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 250: G715-G726.
45. Tso, P., V. Pitts and D.N. Granger. 1985. Role of lymph flow in intestinal chylomicron transport. Am. J. Physiol. 1249: G21-G28.
46. Wang, W., M. Muthuchamy and D.C. Zawieja. 2009. Low density lipoprotein modulates rat mesenteric lymphatic pumping. FASEB J. 23: 764.
47. Gasheva, O.Y., K. Knippa, Z.V. Nepiushchikh, et al. 2007. Age-related alterations of active pumping mechanisms in rat thoracic duct. Microcirculation 14: 827-839.
48. Rutkowski, J.M., K.E. Davis and P.E. Scherer. 2009. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J. 276: 5738-5746.
49. Tammela, T, T.V. Petrova and K. Alitalo. 2005.Molecular lymphangiogenesis: new players. Trends Cell Biol. 15: 434-441.
50. Gale, N.W., G. Hurston, S.F. Hackett, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3: 411-423.
51. Brorson H. 2003. Liposuction in arm lymphedema treatment. Scand. J. Surg. 92: 287-295.
52. Karkkainen, M.J., A. Saaristo, L. Jussila, et al. 2001. Amodel for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. USA 98: 12677-12682.
53. Harvey, N., S. Sriniivasan, M. Dillard, et al. 2005. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat. Genet. 37: 1072-1081.
54. Festa, A., R. D'Agostino JR, G. Howard, et al. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47.
55. Esposito, K. and D. Giugliano. 2004. Themetabolic syndrome and inflammation: association or causation? Nutr. Metab. Cardiovasc. Dis. 14: 228-232.
56. Shah, A., N. Mehta and M.P. Reilly. 2008. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J. Parenter. Enteral. Nutr. 32: 638-644.
57. Hotamisligil, G.S., N.S. Shargill and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91.
58. Tamakoshi, K., H. Yatsuya, T. Kondo, et al. 2003. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic lowgrade inflammatory state. Int. J. Obes. Relat. Metab. Disord. 27: 443-449.
59. Lemieux, I., A. Pascot, D. Prud'homme, et al. 2001. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity.Arterioscler.Thromb.Vasc. Biol. 21: 961-967.
60. Hotamisligil, G.S. 2006. Inflammation and metabolic disorders. Nature 444: 860-867.
61. Severini, C., G. Improta, G. Falconieri-Erspamer, et al. 2002. The tachykinin peptide family. Pharmacol. Rev. 54: 285-322.
62. Gross, K., I. Karagiannides, T. Thomou, et al. 2009. Substance P promotes expansion of human mesenteric preadipocytes through proliferative and anti-apoptotic pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1012-G1019.
63. Maby-El Hajjami, H. and T.V. Petrova. 2008. Developmental andpathological lymphangiogenesis: frommodels tohuman disease. Histochem. Cell Biol. 130: 1063-1078.
64. Johnston, M.G. and J.L. Gordon. 1981. Regulation of lymphatic contractility by arachidonatemetabolites. Nature 293: 294-297.
65. Chan, A.K., N. Vergnolle, M.D. Hollenberg, et al. 2004. Proteinase-activated receptor 2 activationmodulates guinea pig mesenteric lymphatic vessel pacemaker potential and contractile activity. J. Physiol. 560(Pt 2): 563-576.
66. Gao, J., J. Zhao, S.E. Rayner, et al. 1999. Evidence that the ATP-induced increase in vasomotion of guinea-pig mesenteric lymphatics involves an endothelium-dependent release of thromboxane A2. Br. J. Pharmacol. 127: 1597-1602.
67. Mizuno, R., A. Koller and G. Kaley. 1998. Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. Am. J. Physiol. 274(Pt 2): R790-R796.
68. Vergnolle, N., J.L. Wallace, N.W. Bunnett, et al. 2001. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci. 22: 146-152.
69. Zhao, J. and D.F. Van Helden. 2002. ATP-induced endothelium-independent enhancement of lymphatic vasomotion in guinea-pig mesentery involves P2X and P2Y receptors. Br. J. Pharmacol. 137: 477-487.
70. Lewis, G.P. and N.J. Winsey. 1970. The action of pharmacologically active substances on the flow and composition of cat hind limb lymph. Br. J. Pharmacol. 40: 446-460.
71. Haddy, F.J., J.B. Scott and G.J. Grega. 1972. Effects of histamine on lymph protein concentration and flow in the dog forelimb. Am. J. Physiol. 223: 1172-1177.
72. Mcnamee, J.E. 1983.Histamine decreases selectivity of sheep lung blood-lymph barrier. J. Appl. Physiol. 54: 914-918.
73. Amelang, E., C.M. Prasad, R.M. Raymond, et al. 1981. Interactions among inflammatory mediators on edema formation in the canine forelimb. Circ. Res. 49: 298-306.
74. Svensjo, E., S.W. Adamski, K. Su, et al. 1982. Quantitative physiological and morphological aspects of microvascular permeability changes induced by histamine and inhibited by terbutaline. Acta Physiol. Scand. 116: 265-273.
75. Mizuno, R., A. Koller and G. Kaley. 1998. Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. Am. J. Physiol. 274(3 Pt 2): R790- R796.
76. Amerini, S., M. Ziche, S.T. Greiner, et al. 2004. Effects of substance P on mesenteric lymphatic contractility in the rat. Lymphat. Res. Biol. 2: 2-10.
77. Davis, M.J., M.M. Lane, A.M. Davis, et al. 2008. Modulation of lymphatic muscle contractility by the neuropeptide substance P. Am. J. Physiol. Heart Circ. Physiol. 295: H587- H597.
78. Wang, W., Z. Nepiyushchikh, D.C. Zawieja, et al. 2009. Inhibition of myosin light chain phosphorylation decreases rat mesenteric lymphatic contractile activity. Am. J. Physiol. Heart Circ. Physiol. 297: H726-H734.
79. Akopian, V.A., N.V. Balashov and G.F. Khanipov. 1998. Effect of calcitonin gene related peptide on lymphatic vessels. Zh. Evol. Biokhim. Fiziol. 34: 675-682.
80. Hosaka, K., S.E. Rayner, P.Y. Von der Weid, et al. 2006. Calcitonin gene-related peptide activates different signaling pathways in mesenteric lymphatics of guinea pigs. Am. J. Physiol. Heart Circ. Physiol. 290: H813-H822.
81. Ohhashi, T., J.A. Olschowka and D.M. Jacobowitz. 1983. Vasoactive intestinal peptide inhibitory innervation in bovine mesenteric lymphatics. A histochemical and pharmacological study. Circ. Res. 53: 535-538.
82. Esteban, F., M. Muñoz, M.A. González-Moles, et al. 2006. Role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 25: 137-145.
83. Payan, D.G. 1989.Neuropeptides and inflammation: the role of substance P. Annu. Rev. Med. 40: 341-352.
84. Nowicki, M., D. Ostalska-Nowicka, B. Kondraciuk, et al. 2007. The significance of substance P in physiological and malignant haematopoiesis. J. Clin. Pathol. 60: 749-755.
85. Karagiannides, I. and C. Pothoulakis. 2009. Substance P, obesity, and gut inflammation. Curr. Opin. Endocrinol. Diabetes Obes. 16: 47-52.
86. Nougues, J., Y. Reyne, and J.P. Dulor. 1988. Differentiation of rabbit adipocyte precursors in primary culture. Int. J. Obes. 12: 321-333.
87. Karagiannides, I., D. Torres, Y.H. Tseng, et al. 2008. Substance P as a novel anti-obesity target. Gastroenterology 134: 747-755.
88. Pond, C.M. and C.A. Mattacks. 2002. The activation of the adipose tissue associated with lymph nodes during the early stages of an immune response. Cytokine 17: 131-139.
89. Mattacks, C.A., D. Sadler and C.M. Pond. 2003. The cellular structure and lipid/protein composition of adipose tissue surrounding chronically stimulated lymph nodes in rats. J. Anat. 202: 551-561.